Second quarter 2026
Filed Aug 13, 2026Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid reported $1.5 million in EsoGuard revenue and processed 2,770 tests while advancing commercial coverage, but it remained loss-making, operating expenses were $14,275 (in thousands), and cash and cash equivalents declined to $33.4 million from $34.7 million as of December 31, 2025.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $1,474 (in thousands) | – | – |
| EsoGuard related revenuesGAAP | $1.5 million | – | – |
| Cost of revenuesGAAP | $1,445 (in thousands) | – | – |
| Sales and marketingGAAP | $5,757 (in thousands) | – | – |
| General and administrativeGAAP | $5,776 (in thousands) | – | – |
| Research and developmentGAAP | $1,192 (in thousands) | – | – |
| Total operating expensesGAAP | $14,275 (in thousands) | – | – |
| Stock-based compensation expenseother | $1,694 (in thousands) | – | – |
| Depreciation and amortization expenseother | $224 (in thousands) | – | – |
| Interest expense, netother | $(73) (in thousands) | – | – |
| Other (Income) expense, netGAAP | $(1,114) (in thousands) | – | – |
| Net lossGAAP | $(11,687) (in thousands) | – | – |
| Net income (loss) per common share, basic and dilutedGAAP | $(0.08) | – | – |
| Net loss attributable to common stockholdersGAAP | $(14,715) (in thousands) | – | – |
| Preferred Stock dividends and deemed dividendsGAAP | $3,028 (in thousands) | – | – |
| EBITDAnon-GAAP | $(11,536) (in thousands) | – | – |
| Change in FV convertible debtnon-GAAP | $(1,041) (in thousands) | – | – |
| Non-GAAP adjusted lossnon-GAAP | $(10,854) (in thousands) | – | – |
| Basic and Diluted shares outstandingother | 183,124 | – | – |
| Non-GAAP adjusted (loss) income per sharenon-GAAP | $(0.06) | – | – |
| EsoGuard Esophageal DNA Tests processedother | 2,770 | – | – |
| Cash and cash equivalentsother | $33.4 million as of June 30, 2026 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| EsoGuardLucid processed 2,770 EsoGuard Esophageal DNA Tests and secured a commercial coverage policy from Concert that has already been adopted by multiple Concert client health plans. | $1.5 million | – | – |
What drove it
- Recognized $1.5 million in EsoGuard revenue for 2Q26.
- Processed 2,770 EsoGuard Esophageal DNA Tests in 2Q26.
- Secured a commercial coverage policy for EsoGuard from Concert, a healthcare technology company recently acquired by Lyric.
- The Concert policy recognizes EsoGuard as medically necessary for patients meeting established screening criteria and has already been adopted by multiple Concert client health plans.
- Developed a health economic cost-effectiveness model for EsoGuard screening, with preliminary results demonstrating improved clinical outcomes and cost-effectiveness.
- Lucid stated that it accelerated engagement with the VA and major health systems.
Concerns
- GAAP net loss attributable to common stockholders was $(14,715) (in thousands), inclusive of $3,028 (in thousands) of Preferred Stock dividends and deemed dividends.
- Total operating expenses were $14,275 (in thousands), compared with $12,547 (in thousands) in the prior-year period.
- Sales and marketing expense was $5,757 (in thousands), compared with $4,007 (in thousands) in the prior-year period.
- Cash and cash equivalents declined to $33.4 million as of June 30, 2026 from $34.7 million as of December 31, 2025.
- The company stated it is awaiting a positive draft Medicare coverage policy for EsoGuard.
What to watch
- A positive draft Medicare coverage policy for EsoGuard.
- Adoption of the Concert laboratory testing policy by additional client health plans.
- Commercial engagement with the VA and major health systems.
- Revenue and test-processing progression for EsoGuard.
- Cash and cash equivalents following the $33.4 million balance reported as of June 30, 2026.
Balance sheet and cash flow
- Cash and cash equivalents were $33.4 million as of June 30, 2026, compared to $34.7 million as of December 31, 2025.
Analysis
Lucid reported $1.5 million in EsoGuard related revenue for the second quarter of 2026 and processed 2,770 EsoGuard tests. The reconciliation table reported revenue of $1,474 (in thousands), compared with $1,163 (in thousands) for the three months ended June 30, 2025. The release did not provide a reported percentage growth rate, prior-quarter revenue, or a revenue breakdown beyond EsoGuard related revenues.
Commercial execution centered on reimbursement and access. Lucid secured its first laboratory benefit manager coverage policy through Concert, which recognizes EsoGuard as medically necessary for patients meeting established screening criteria. The company said multiple Concert client health plans have already adopted the policy. Management also cited accelerated engagement with the VA and major health systems and preliminary health-economic model results demonstrating improved clinical outcomes and cost-effectiveness.
The expense base remained substantially larger than revenue. Total operating expenses were $14,275 (in thousands), versus $12,547 (in thousands) in the prior-year period, with sales and marketing at $5,757 (in thousands), compared with $4,007 (in thousands). GAAP net loss was $(11,687) (in thousands), while net loss attributable to common stockholders was $(14,715) (in thousands), inclusive of $3,028 (in thousands) of Preferred Stock dividends and deemed dividends. Non-GAAP adjusted loss was $(10,854) (in thousands), compared with $(9,946) (in thousands) in the prior-year period.
Liquidity is an important focus. Cash and cash equivalents were $33.4 million as of June 30, 2026, compared with $34.7 million as of December 31, 2025. The filing did not report operating cash flow, free cash flow, debt, capital-return activity, or forward financial guidance. The principal disclosed catalyst is a positive draft Medicare coverage policy for EsoGuard, alongside further commercial-plan adoption and progress with VA and health-system engagement.
Management, verbatim
Lucid’s commercial momentum strengthened throughout the second quarter and in recent weeks.
Lishan Aklog, M.D., Chairman and Chief Executive Officer
We continue to advance multiple commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard.
Lishan Aklog, M.D., Chairman and Chief Executive Officer
Progress across these initiatives positions Lucid to capitalize on EsoGuard’s significant clinical and commercial opportunity, while increasing the company’s visibility and thereby expanding opportunities for broader strategic engagement.
Lishan Aklog, M.D., Chairman and Chief Executive Officer
Not in the filing
stated, not guessed- Gross margin and gross-margin comparison
- Operating income or operating loss
- Revenue growth percentage
- Prior-quarter revenue and expense comparisons
- Segment revenue breakdown beyond EsoGuard related revenues
- Operating cash flow
- Free cash flow
- Debt balance
- Capital returns, including share repurchases and dividends
- Forward financial guidance
- Tax rate
- Cash-flow statement metrics
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.